Literature DB >> 20573673

Predictive factors of difficult implantation procedure in cardiac resynchronization therapy.

Laurence Bisch1, Antoine Da Costa, Virginie Dauphinot, Cécile Romeyer-Bouchard, Lila Khris, Alassane M'baye, Karl Isaaz.   

Abstract

AIMS: The usefulness of cardiac resynchronization therapy (CRT) in patients with congestive heart failure is offset by its long, user-dependent, and technical procedure. No studies have been published regarding factors related to CRT implantation procedure duration and X-ray exposure. Additionally, only a few studies have investigated the predictive factors of primary left ventricular (LV) lead implant failure. The aim of this prospective study was two-fold: (i) to evaluate the prevalence and predictive factors of prolonged CRT implantation procedure and (ii) to identify the predictive factors of primary LV lead implantation failure. METHODS AND
RESULTS: Between November 2008 and September 2009, 128 consecutive patients underwent CRT implantation; of these, 22 patients (17.2%) were excluded because of CRT generator replacement. Population characteristics were a mean age of 69 +/- 10 years, 28.3% female, New York Heart Association class 3.2 +/- 0.3, LV ejection fraction (LVEF; 29 +/- 6%), and QRS width 146 +/- 23 ms. Cardiac resynchronization therapy implantation was attempted in 106 patients, and first LV lead implantation was obtained in 96 of 106 patients (90.5% primary success). Ten primary implantations failed (9.5%), due to unsuccessful LV lead implants. A second procedure was successfully attempted in six patients with a second more experienced operator (5.7%). Among the remaining four patients, one patient required a surgical epicardial LV lead implantation, and the implantation was not reattempted in the other three patients. The overall success rate of CRT system implantation was 96.2% (102 of 106 patients). Procedure parameters were as follows: LV threshold (1.4 +/- 0.9 V); LV wave amplitude (15 +/- 8 mV); LV impedance (874 +/- 215 ohm); median procedure time (skin to skin), 55 min (45-80); and median of procedure fluoroscopy time, 11 min (6.2-29). In 24 patients (22.6%), difficult procedures requiring >or=85 min of implantation duration occurred. By univariate analysis, predictive factors of difficult implantation were LV ejection fraction (25.6 +/- 6 vs. 30.2 +/- 8%; P = 0.02), LV end-diastolic diameter (72.4 +/- 11 vs. 66 +/- 11 mm; P = 0.01), LV end-systolic diameter (LVESD; 62 +/- 12 vs. 56 +/- 12 mm, P = 0.04), and the operator's experience (very experienced operator vs. less experienced operator, P = 0.006). By multivariate analysis, only primary LV lead implantation failure, LVESD, and operator's experience were independently associated with difficult procedures. In this patient subset with primary LV lead implant failure (n = 10), the only independent predictive factor was the LV end-systolic volume (P = 0.03).
CONCLUSION: In this study, the rate of difficult CRT device implantation procedures approached 25%. Both the degree of LV dysfunction and the operator's experience were independent predictors of surgical difficulties. Left ventricular end-systolic volume was the only independent predictor of primary LV lead implant failure.

Entities:  

Mesh:

Year:  2010        PMID: 20573673     DOI: 10.1093/europace/euq146

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  9 in total

1.  Elimination of phrenic nerve stimulation occurring during CRT: follow-up in patients implanted with a novel quadripolar pacing lead.

Authors:  Paresh A Mehta; Anoop K Shetty; Mark Squirrel; Julian Bostock; C Aldo Rinaldi
Journal:  J Interv Card Electrophysiol       Date:  2011-07-21       Impact factor: 1.900

Review 2.  Optimizing CRT - Do We Need More Leads and Delivery Methods.

Authors:  Pieter Martens; Frederik Hendrik Verbrugge; Wilfried Mullens
Journal:  J Atr Fibrillation       Date:  2015-04-30

3.  Predictors of fluoroscopy time and procedural failure during biventricular device implantation.

Authors:  Jonathan C Hsu; Nitish Badhwar; Byron K Lee; Vasanth Vedantham; Zian H Tseng; Gregory M Marcus
Journal:  Am J Cardiol       Date:  2012-04-05       Impact factor: 2.778

4.  Use of a quadripolar left ventricular lead to achieve successful implantation in patients with previous failed attempts at cardiac resynchronization therapy.

Authors:  Anoop K Shetty; Simon G Duckett; Julian Bostock; Eric Rosenthal; C Aldo Rinaldi
Journal:  Europace       Date:  2011-02-22       Impact factor: 5.214

5.  A Review of the Key Clinical Trials of 2014.

Authors:  Peter McKavanagh; Claire McCune; Ian B Menown
Journal:  Cardiol Ther       Date:  2015-03-27

6.  Seven years of use of implantable cardioverter-defibrillator therapies: a nationwide population-based assessment of their effectiveness in real clinical settings.

Authors:  Arn Migowski; Antonio Luiz Ribeiro; Marilia Sá Carvalho; Vitor Manuel Pereira Azevedo; Rogério Brant Martins Chaves; Lucas de Aquino Hashimoto; Carolina de Aquino Xavier; Regina Maria de Aquino Xavier
Journal:  BMC Cardiovasc Disord       Date:  2015-03-13       Impact factor: 2.298

7.  The use of lubricating solution as a novel method in facilitating left ventricular lead placement: A case series.

Authors:  Pedram Kazemian; Andrew Mathew; Raffaele Corbisiero; Michael Flynn
Journal:  HeartRhythm Case Rep       Date:  2020-03-13

8.  The Use of a Quadripolar Left Ventricular Lead Increases Successful Implantation Rates in Patients with Phrenic Nerve Stimulation and/or High Pacing Thresholds Undergoing Cardiac Resynchronisation Therapy with Conventional Bipolar Leads.

Authors:  Marc-Alexander Ohlow; Bernward Lauer; Michele Brunelli; Yunis Daralammouri; Christoph Geller
Journal:  Indian Pacing Electrophysiol J       Date:  2013-03-07

Review 9.  Understanding non-response to cardiac resynchronisation therapy: common problems and potential solutions.

Authors:  Benjamin J Sieniewicz; Justin Gould; Bradley Porter; Baldeep S Sidhu; Thomas Teall; Jessica Webb; Gerarld Carr-White; Christopher A Rinaldi
Journal:  Heart Fail Rev       Date:  2019-01       Impact factor: 4.214

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.